1-10 of 10
Frédéric Triebel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PD14-08: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients

Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, Steve Chan, Frederik Marme, Carolina Pia Schröder, Jens Huober, Jill Wagemans, Peter Vuylsteke, Jean-Philippe Jacquin, Etienne Brain, Sherko Kümmel, Zsuzsanna Pápai, Luca Perjesi, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD14-08.
https://doi.org/10.1158/1538-7445.SABCS20-PD14-08
Published: 15 February 2021
View article titled, Abstract PD14-08: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
Journal Articles

Abstract CT202: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab

Martin Forster, Enriqueta Felip, Bernhard Doger, Margarita Majem, Enric Carcereny, Julio Peguero, Pawan Bajaj, Tim Clay, Matthew Krebs, Patricia Roxburgh, Leora Horn, Frederic Triebel
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT202.
https://doi.org/10.1158/1538-7445.AM2020-CT202
Published: 15 August 2020
View article titled, Abstract CT202: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab
Journal Articles

Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Luc Dirix, Hans Wildiers, Manon T Huizing, Eveline De Cuypere, Carolina P Schröder, Anne C Armstrong, Jans Huober, Frederik Marmé, Andreas Schneeweiss, Sarah Khan, Fréderic Triebel
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): OT1-01-05.
https://doi.org/10.1158/1538-7445.SABCS19-OT1-01-05
Published: 15 February 2020
View article titled, Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer
Journal Articles

LAG-3 ( CD223) molecule is preferentially expressed in human CD4+CD25+ T cells displaying suppressor activity

Chiara Castelli, Francesca Rini, Chiara Casati, Chiara Camisaschi, Arabella Mazzocchi, Frederic Triebel, Giorgio Parmiani
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 221.
Published: 01 May 2007
View article titled, LAG-3 ( CD223) molecule is preferentially expressed in human CD4+CD25+ T cells displaying suppressor activity
Journal Articles

LAG-3 Enables DNA Vaccination to Persistently Prevent Mammary Carcinogenesis in HER-2/ neu Transgenic BALB/c Mice

Paola Cappello, Frederic Triebel, Manuela Iezzi, Cristiana Caorsi, Elena Quaglino, Pier-Luigi Lollini, Augusto Amici, Emma Di Carlo, Piero Musiani, Mirella Giovarelli, Guido Forni
Journal: Cancer Research
Cancer Res (2003) 63 (10): 2518–2525.
Published: 15 May 2003
View article titled, LAG-3 Enables DNA Vaccination to Persistently Prevent Mammary Carcinogenesis in HER-2/ <em>neu</em> Transgenic BALB/c Mice
Open the PDF for LAG-3 Enables DNA Vaccination to Persistently Prevent Mammary Carcinogenesis in HER-2/ <em>neu</em> Transgenic BALB/c Mice in another window
Journal Articles

T-Cell Receptor Repertoire in Neuroblastoma Patients

Dominique Valteau, Véronique Scott, Guislaine Carcelain, Olivier Hartmann, Bernard Escudier, Thierry Hercend, Frédéric Triebel
Journal: Cancer Research
Cancer Res (1996) 56 (2): 362–369.
Published: 01 January 1996
View article titled, T-Cell Receptor Repertoire in Neuroblastoma Patients
Open the PDF for T-Cell Receptor Repertoire in Neuroblastoma Patients in another window
Journal Articles

In Vivo Local Expansion of Clonal T Cell Subpopulations in Renal Cell Carcinoma

Catherine Gaudin, Pierre-Yves Dietrich, Sylvie Robache, Maryvonne Guillard, Bernard Escudier, Marie-Josée Terrier Lacombe, Anil Kumar, Frédéric Triebel, Anne Caignard
Journal: Cancer Research
Cancer Res (1995) 55 (3): 685–690.
Published: 01 February 1995
View article titled, <em>In Vivo</em> Local Expansion of Clonal T Cell Subpopulations in Renal Cell Carcinoma
Open the PDF for <em>In Vivo</em> Local Expansion of Clonal T Cell Subpopulations in Renal Cell Carcinoma in another window
Journal Articles

Evidence for T-Cell Clonal Expansion in a Patient with Squamous Cell Carcinoma of the Head and Neck

Anne Caignard, Pierre Yves Dietrich, Valérie Morand, Annick Lim, Christophe Pannetier, Anne Marie Leridant, Thierry Hercend, Jos Even, Philippe Kourilsky, Frédéric Triebel
Journal: Cancer Research
Cancer Res (1994) 54 (5): 1292–1297.
Published: 01 March 1994
View article titled, Evidence for T-Cell Clonal Expansion in a Patient with Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Evidence for T-Cell Clonal Expansion in a Patient with Squamous Cell Carcinoma of the Head and Neck in another window
Journal Articles

Evidence for in Situ Amplification of Cytotoxic T-Lymphocytes with Antitumor Activity in a Human Regressive Melanoma

Andreas Mackensen, Laurent Ferradini, Guislaine Carcelain, Frederic Triebel, Florence Faure, Sophie Viel, Thierry Hercend
Journal: Cancer Research
Cancer Res (1993) 53 (15): 3569–3573.
Published: 01 August 1993
View article titled, Evidence for <em>in Situ</em> Amplification of Cytotoxic T-Lymphocytes with Antitumor Activity in a Human Regressive Melanoma
Open the PDF for Evidence for <em>in Situ</em> Amplification of Cytotoxic T-Lymphocytes with Antitumor Activity in a Human Regressive Melanoma in another window
Journal Articles

Analysis of T-Cell Receptor α/β Variability in Lymphocytes Infiltrating a Melanoma Metastasis

Laurent Ferradini, Sergio Roman-Roman, José Azocar, Marie-Françoise Avril, Sophie Viel, Frédéric Triebel, Thierry Hercend
Journal: Cancer Research
Cancer Res (1992) 52 (17): 4649–4654.
Published: 01 September 1992
View article titled, Analysis of T-Cell Receptor α/β Variability in Lymphocytes Infiltrating a Melanoma Metastasis
Open the PDF for Analysis of T-Cell Receptor α/β Variability in Lymphocytes Infiltrating a Melanoma Metastasis in another window